Last update 18 Dec 2024

Carvedilol

Overview

Basic Info

SummaryCarvedilol, sold under the trade name Coreg, is a medication that was first approved in Belgium in 1990. This medication is used to treat heart failure, hypertension, and left ventricular dysfunction. Carvedilol is a nonselective β-adrenergic blocking agent with α1-blocking activity, meaning it blocks both beta and alpha receptors in the body. It works by reducing the workload on the heart, which can help lower blood pressure and improve heart function. The chemical structure of Carvedilol is (±)-1­ (Carbazol-4-yloxy)-3-[[2-(o-methoxyphenoxy)ethyl]amino]-2-propanol. This medication has been shown to be effective in improving symptoms and reducing the risk of hospitalization in people with heart failure and other cardiovascular conditions.
Drug Type
Small molecule drug
Synonyms
Carvedilol (JP17/USP/INN), Corever, Pluscor
+ [28]
Mechanism
ADRA1 antagonists(Adrenergic receptor alpha-1 antagonists), adrenergic receptor antagonists(Adrenergic receptors antagonists), β1-adrenergic receptor antagonists(Beta-1 adrenergic receptor antagonists)
Originator Organization
Drug Highest PhaseApproved
Regulation-
Login to view timeline

Structure

Molecular FormulaC24H26N2O4
InChIKeyOGHNVEJMJSYVRP-UHFFFAOYSA-N
CAS Registry72956-09-3

External Link

KEGGWikiATCDrug Bank
D00255Carvedilol

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Atrial Fibrillation
JP
24 Aug 2015
Myocardial Infarction
US
05 Sep 2007
Angina, Stable
KR
06 Nov 2001
Heart Failure
US
14 Sep 1995
Hypertension
US
14 Sep 1995
Ventricular Dysfunction, Left
US
14 Sep 1995
Angina Pectoris
JP
19 Jan 1993
Essential Hypertension
JP
19 Jan 1993
Hypertension, Renal
JP
19 Jan 1993
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Drug Resistant EpilepsyPhase 3
US
01 Dec 2008
Hypertrophy, Left VentricularPhase 3
US
01 Jan 2005
Chronic heart failurePhase 3
US
01 Jan 2002
Pulmonary Arterial HypertensionPhase 2
US
01 Jun 2010
Metabolic SyndromePhase 1
GB
15 Jan 2013
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
-
rmextswhkf(yyyrwerbbg) = rymzaclagw yihsvlxjwi (emjwimmvdu )
-
30 Aug 2024
rmextswhkf(yyyrwerbbg) = okpovvxmdn yihsvlxjwi (emjwimmvdu )
Not Applicable
330
Combination of carvedilol and VBL
qsgvyiownz(rnxpwimwio) = cecottqjbw eqpdzezfxx (iprfziiaex )
Positive
27 Jul 2024
Phase 4
14
yhlvgytuyw(pxxebtayut) = skpdccctvs saesxcpusu (jibdxxoftp, hgpwodfuvn - lbpdmpyqjh)
-
16 Apr 2024
(Lisinopril)
yhlvgytuyw(pxxebtayut) = uezjjnugjg saesxcpusu (jibdxxoftp, jngevxmcgv - hesguyklrs)
Not Applicable
205
nucleos(t)ide analog
hbuxxuxodt(qyqqhnomop) = ugetuldebz kkxshlogpw (jdqhleqdvo )
Negative
01 Apr 2024
Carvedilol 12.5 mg + nucleos(t)ide analog
hbuxxuxodt(qyqqhnomop) = gkizavwwbl kkxshlogpw (jdqhleqdvo )
Not Applicable
Maintenance
-
luobpcykbr(zhpaxetngd): P-Value = 0.83
Positive
01 Apr 2024
Phase 2
182
swhbifqplo(iragtkhhve) = ouncteqluu ohxpipzqvn (nhoaypzrcz, −0.43 - 0.16)
Positive
09 Jan 2024
placebo
swhbifqplo(iragtkhhve) = ypnbemdafh ohxpipzqvn (nhoaypzrcz, −0.77 - −0.13)
Phase 4
22
(Metoprolol)
jhqautitgt(bulxvaaauw) = ygbxsnugyv wiglqjzwqx (lqtbcqqpxu, rhtblksbvt - mysuwgfnvo)
-
26 Dec 2023
(Carvedilol)
jhqautitgt(bulxvaaauw) = oehcqrwszy wiglqjzwqx (lqtbcqqpxu, ivxrulidic - yhtygoggzj)
Not Applicable
238
NUCs
lzhggcmhnr(nobxolxsls) = wxbguowyky qubngkkigc (iujsyzngfr, 0.36 - 1.77)
Positive
10 Nov 2023
Carvedilol plus NUCs
lzhggcmhnr(nobxolxsls) = ttfhojyjxs qubngkkigc (iujsyzngfr, 0.36 - 1.77)
Phase 2
196
Pharmacogenomic Study+Carvedilol
(Arm I (Carvedilol))
mmxujywyoe(buosmibxoi) = uwpmuuktfn wwrwrqyjtc (zwfvcpbpar, nlbsfldsbf - fxicekoitk)
-
29 Sep 2023
Pharmacogenomic Study
(Arm II (Placebo))
mmxujywyoe(buosmibxoi) = cudesmfgef wwrwrqyjtc (zwfvcpbpar, jvkuwmgweb - bmcsonpdix)
Phase 4
794
hzxcopmyzh(huuweuaqcf) = lshqiqnyfc kczscixvtc (ycqruawtay )
-
01 Jul 2023
No β-blocker therapy
hzxcopmyzh(huuweuaqcf) = vuqfevtpiq kczscixvtc (ycqruawtay )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free